225 related articles for article (PubMed ID: 10471566)
1. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
[TBL] [Abstract][Full Text] [Related]
2. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
3. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.
Yardley V; Croft SL
Antimicrob Agents Chemother; 1997 Apr; 41(4):752-6. PubMed ID: 9087483
[TBL] [Abstract][Full Text] [Related]
4. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
5. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.
Falk R; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 1999 Aug; 43(8):1975-81. PubMed ID: 10428922
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of amino-containing drugs to polysaccharides by tosylation: amphotericin B-arabinogalactan conjugates.
Ehrenfreund-Kleinman T; Golenser J; Domb AJ
Biomaterials; 2004 Jul; 25(15):3049-57. PubMed ID: 14967538
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
8. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
9. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.
Corware K; Harris D; Teo I; Rogers M; Naresh K; Müller I; Shaunak S
Biomaterials; 2011 Nov; 32(31):8029-39. PubMed ID: 21807409
[TBL] [Abstract][Full Text] [Related]
10. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
[TBL] [Abstract][Full Text] [Related]
11. The effect of amphotericin b derivatives on Leishmania and immune functions.
Ehrenfreund-Kleinman T; Domb AJ; Jaffe CL; Nasereddin A; Leshem B; Golenser J
J Parasitol; 2005 Feb; 91(1):158-63. PubMed ID: 15856892
[TBL] [Abstract][Full Text] [Related]
12. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.
Paul M; Durand R; Fessi H; Rivollet D; Houin R; Astier A; Deniau M
Antimicrob Agents Chemother; 1997 Aug; 41(8):1731-4. PubMed ID: 9257750
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
[TBL] [Abstract][Full Text] [Related]
16. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi.
Nishi KK; Antony M; Mohanan PV; Anilkumar TV; Loiseau PM; Jayakrishnan A
Pharm Res; 2007 May; 24(5):971-80. PubMed ID: 17372682
[TBL] [Abstract][Full Text] [Related]
18. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice.
Nelson KG; Bishop JV; Ryan RO; Titus R
Antimicrob Agents Chemother; 2006 Apr; 50(4):1238-44. PubMed ID: 16569834
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
20. Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan.
Falk R; Hacham M; Nyska A; Foley JF; Domb AJ; Polacheck I
J Antimicrob Chemother; 2005 May; 55(5):713-20. PubMed ID: 15814605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
